SiRNA medicine and pharmaceutical application thereof
By designing specific sequences and modified siRNAs, the problems of poor stability and great cytotoxicity of siRNA in the prior art are solved, and effective inhibition and stability improvement of HBV are achieved, and the prevention and treatment of HBV-related diseases are used.
Patent Information
- Application Number
- CN202410717713.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2024-06-04
- Publication Date
- 2024-12-06
AI Technical Summary
The existing siRNA has poor stability and is problematic of cytotoxicity, making it difficult to effectively inhibit the expression and replication of HBV.
A siRNA is designed that includes modified or unmodified nucleotide sequences that inhibit HBV expression and replication by forming a silencing complex and using specific nucleotide sequences and modifications to improve the expression and replication of HBV. Stability and toxicity reduction.
Effectively inhibits the expression and replication of HBV, improves the stability and safety of drugs, has good serum stability and low cytotoxicity, and can prevent and treat related diseases caused by HBV.
Smart Images

Figure BDA0004876052030000041 
Figure BDA0004876052030000052 
Figure BDA0004876052030000061
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of small interfering nucleic acid drugs. Specifically, the present invention relates to an siRNA drug and its pharmaceutical use. More specifically, the present invention relates to an siRNA, an siRNA conjugate, a pharmaceutical composition and their use in pharmaceutical manufacturing. Background Art
[0002] RNA interference (RNAi) is a phenomenon in which double-stranded RNA (dsRNA) molecules shut down the expression of homologous genes or silence the expression of the gene at the mRNA level. RNA interference technology is also vividly called gene knock-down or gene silencing. It is a typical post-transcriptional gene regulation method, also known as post-transcriptional gene silencing (PTGS). The earliest report on RNA interference appeared in 1990, when two different research groups simultaneously reported the RNA interference phenomenon in transgenic plants. Later, RNA interference was observed in almost all eukaryotic organisms such as nematodes, fruit flies, zebrafish and mice. In 1999, Hamilton and Baulcombe detected RNA fragments with a length of 21-25 nucleotides in plants with RNA interference. These RNA fragments were proved to be necessary for RNA interference and were called small interfering nucleic acids (siRNA). Double-stranded siRNA forms an RNA-induced silencing complex (RISC) with cell-derived related enzymes and proteins. During RNA interference, the sense strand in the double-stranded siRNA is excluded from the complex, and the antisense strand guides RISC to bind to the homologous site of the target mRNA. The target mRNA is then degraded by ribonuclease III in the complex, thereby shutting down the expression of the target gene.
[0003] However, due to the poor stability of small interfering nucleic acids (siRNA), it is easily degraded by nucleases in vivo. At present, chemical modification of synthetic siRNA is usually adopted to increase the serum stability of siRNA, so as to effectively inhibit the target gene. However, the existing siRNA modification scheme has the problem of blindly introducing a large number of modifications, which leads to the cytotoxicity of the modified small interfering nucleic acids.
[0004] Therefore, it is urgent to develop a siRNA with strong stability and low cytotoxicity. Summary of the invention
[0005] The present invention aims to solve one of the technical problems existing in the prior art to at least a certain extent. To this end, the present invention provides a siRNA that can inhibit the expression and replication of HBV and block one or more genotypes of HBV from entering liver cells.
[0006] In one aspect of the present invention, the present invention proposes a siRNA, wherein each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA includes a sense strand and an antisense strand, wherein the antisense strand has at least a partial base-paired complementary region with the sense strand; wherein the sense strand includes one of the nucleotide sequences shown in SEQ ID NO:1 to SEQ ID NO:150, or has a difference of no more than 5 nucleotides therefrom; and the antisense strand includes one of the nucleotide sequences shown in SEQ ID NO:151 to SEQ ID NO:300, or has a difference of no more than 5 nucleotides therefrom. The inventors experimentally designed that the above-mentioned suitable small interfering RNA (siRNA) forms a silencing complex (RNA-induced silencing complex, RISC), and complementarily pairs with the sequence of the mRNA of the target gene (hepatitis B virus, referred to as hepatitis B virus, HBV), thereby degrading the mRNA of the hepatitis B virus, thereby inhibiting the expression and replication of HBV, and can effectively prevent and / or treat related diseases caused by HBV. According to an embodiment of the present invention, the above-mentioned siRNA may further include at least one of the following technical features:
[0007] According to an embodiment of the present invention, the positive strand comprises one of the following nucleotide sequences, or a difference therefrom of no more than 5 nucleotides: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:58, SEQ ID NO:69, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126 NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:140, SEQ ID NO:148 and SEQ ID NO:150;and / or the antisense strand comprises one of the following nucleotide sequences, or differs therefrom by no more than 5 nucleotides: SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 196, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 208, SEQ ID NO: 219, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:290, SEQ ID NO:298 and SEQ ID NO:300. ;
[0008] According to an embodiment of the present invention, the sense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO: 12, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 93, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 129 and SEQ ID NO: 130; and / or, the antisense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO: 162, SEQ ID NO: 170, SEQ ID NO: 190, SEQ ID NO: 243, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 271, SEQ ID NO: NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:279 and SEQ ID NO:280.
[0009] According to an embodiment of the present invention, the siRNA comprises one of the following:
[0010] A sense strand having the nucleotide sequence shown in SEQ ID NO: 12 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 162 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0011] A sense strand having the nucleotide sequence shown in SEQ ID NO: 20 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 170 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0012] A sense strand having the nucleotide sequence shown in SEQ ID NO:40 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO:190 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0013] A sense strand having the nucleotide sequence shown in SEQ ID NO: 93 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 243 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0014] A sense strand having the nucleotide sequence shown in SEQ ID NO: 97 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 247 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0015] A sense strand having the nucleotide sequence shown in SEQ ID NO: 98 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 248 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0016] A sense strand having the nucleotide sequence as shown in SEQ ID NO: 99 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence as shown in SEQ ID NO: 249 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0017] A sense strand having the nucleotide sequence shown in SEQ ID NO: 115 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 265 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0018] A sense strand having the nucleotide sequence shown in SEQ ID NO: 116 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 266 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0019] A sense strand having the nucleotide sequence shown in SEQ ID NO: 121 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 271 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0020] A sense strand having the nucleotide sequence shown in SEQ ID NO: 123 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 273 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0021] A sense strand having the nucleotide sequence shown in SEQ ID NO: 124 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 274 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0022] A sense strand having the nucleotide sequence shown in SEQ ID NO: 125 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 275 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0023] A sense strand having the nucleotide sequence shown in SEQ ID NO: 129 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 279 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;
[0024] The sense strand has the nucleotide sequence shown in SEQ ID NO: 130 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and the antisense strand has the nucleotide sequence shown in SEQ ID NO: 280 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides.
[0025] According to an embodiment of the present invention, the sense strand and / or antisense strand comprises a 3' overhang and / or a 5' overhang, and the 3' overhang or the 5' overhang comprises at least one nucleotide.
[0026] According to an embodiment of the present invention, the 3' overhang or the 5' overhang comprises at least 2 nucleotides.
[0027] According to an embodiment of the present invention, the sense strand and / or antisense strand comprises a 3' overhang, and the 3' overhang comprises 2 nucleotides.
[0028] According to an embodiment of the present invention, the sense chain contains 5'-GGUUUUUCUUGUUGACAAA-3' (SEQ ID NO: 330), and the length of the sense chain does not exceed 21 nucleotides, the antisense chain contains 5'-UUUGUCAACAAGAAAAACCCC-3' (SEQ ID NO: 190), and the length of the antisense chain does not exceed 23 nucleotides, and each nucleotide in the sense chain and the reaction chain is a modified nucleotide.
[0029] According to an embodiment of the present invention, the sense strand and / or the antisense strand includes at least one modified nucleotide, and the modified nucleotide is independently and optionally selected from at least one of the following: non-natural base nucleotides, deoxynucleotides, 2'-fluoro-modified nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl-modified nucleotides, 2'-methoxyethyl-modified nucleotides, 2'-alkyl-modified nucleotides, 2'-O-alkyl-modified nucleotides, locked nucleotides, non-locked nucleotides, configuration-restricted nucleotides, 2'-allyl-modified nucleotides, abasic nucleotides, morpholino nucleotides, tetrahydropyran-modified nucleotides, 1,5-anhydrohexitol-modified nucleotides, cyclohexenyl-modified nucleotides, PEG-modified nucleotides, 5'-phosphoramidate-modified nucleotides, 5'-phosphorothioate-modified nucleotides, 5'-methylphosphonate-modified nucleotides, 5'-phosphate mimetic-modified nucleotides, and 5'-methylated cytosine-modified nucleotides.
[0030] According to an embodiment of the present invention, all nucleotides in the sense strand and / or the antisense strand are modified nucleotides, and the modified nucleotides are independently and optionally selected from at least one of 2'-methoxy modified nucleotides, 2'-fluoro modified nucleotides and 5'-phosphorothioate modified nucleotides.
[0031] According to an embodiment of the present invention, in the sense strand and / or the antisense strand, the 2'-fluoro-modified nucleotides are present at the following positions:
[0032] The nucleotides at the 5' end of the sense strand are the 5th, 7th, 8th and 9th nucleotides of the starting point; and / or
[0033] The nucleotides at the 5' end of the antisense strand are the 2nd, 6th, 8th, 9th, 14th and 16th nucleotides of the starting point.
[0034] According to an embodiment of the present invention, in the sense strand and / or the antisense strand, 5'-phosphorothioate-modified nucleotides are present at the following positions:
[0035] The nucleotides at the 5' end of the sense strand are the 1st and 2nd nucleotides of the starting point; and / or
[0036] The nucleotides at the 5' end of the antisense strand are the 1st and 2nd positions of the starting point, and / or the nucleotides at the 3' end of the antisense strand are the 2nd and 3rd positions of the starting point.
[0037] According to an embodiment of the present invention, in the sense strand and / or the antisense strand, the 2'-methoxy modified nucleotides are present at the following positions:
[0038] The nucleotides at the 5' end of the sense strand are the 1st, 2nd, 3rd, 4th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th and 19th nucleotides of the starting point; and / or
[0039] The nucleotide at the 5' end of the antisense strand is the 1st, 3rd, 4th, 5th, 7th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th, 20th or 21st nucleotide of the starting point.
[0040] According to an embodiment of the present invention, in the sense strand and / or the antisense strand, 2'-methoxy-modified nucleotides, 2'-fluoro-modified nucleotides and 5'-phosphorothioate-modified nucleotides are present at the following positions:
[0041] The nucleotides at the 5' end of the sense strand are the 1st, 2nd, 3rd, 4th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th and 19th nucleotides of the starting point; and / or
[0042] The nucleotide at the 5' end of the antisense strand is the 1st, 3rd, 4th, 5th, 7th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th, 20th or 21st nucleotide of the starting point; and / or
[0043] The nucleotides at the 5' end of the sense strand are the 5th, 7th, 8th and 9th nucleotides of the starting point; and / or
[0044] The nucleotides at the 5' end of the sense strand are the 1st and 2nd nucleotides of the starting point; and / or
[0045] The nucleotides at the 5' end of the antisense strand are the 2nd, 6th, 8th, 9th, 14th and 16th nucleotides of the starting point; and / or
[0046] The nucleotides at the 5' end of the antisense strand are the first and second positions of the starting point, and / or the nucleotides at the 3' end of the antisense strand are the second and third positions of the starting point.
[0047] According to an embodiment of the present invention, the siRNA comprises one of the following:
[0048]
[0049]
[0050] In the sense strand and the antisense strand, a, g, c and u are 2'-O-methyl (2'-OMe) A, 2'-OMe G, 2'-OMeC and 2'-OMe U, respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U, respectively; and s indicates that the nucleotide has a 5'-phosphorothioate modification.
[0051] According to an embodiment of the present invention, the siRNA includes one of siRNA ID NO: 152, siRNA ID NO: 153, siRNA ID NO: 155, siRNA ID NO: 162, siRNA ID NO: 163, siRNA ID NO: 164, siRNA ID NO: 165 and siRNA ID NO: 166:
[0052]
[0053] In the sense strand and the antisense strand, a, g, c and u are 2'-O-methyl (2'-OMe) A, 2'-OMe G, 2'-OMeC and 2'-OMe U, respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U, respectively; and s indicates that the nucleotide has a 5'-phosphorothioate modification.
[0054] In another aspect of the present invention, the present invention provides a siRNA conjugate. According to an embodiment of the present invention, the siRNA conjugate comprises: the aforementioned siRNA of the present invention; a ligand, wherein the siRNA is connected to the ligand. The siRNA conjugate of the present invention can deliver the drug to cells well due to the addition of the ligand, further improve the degradation of the mRNA of the hepatitis B virus, and can effectively prevent and / or treat related diseases caused by HBV.
[0055] According to an embodiment of the present invention, the siRNA conjugate of the present invention may further include at least one of the following technical features:
[0056] According to an embodiment of the present invention, the ligand is connected to the sense strand and / or the antisense strand.
[0057] According to an embodiment of the present invention, the ligand is connected to the sense strand and / or antisense strand via a phosphorothioate bond or a phosphate bond.
[0058] According to an embodiment of the present invention, the ligand is connected to the 5' end or the 3' end of the sense strand; or, the ligand is connected to the 5' end or the 3' end of the antisense strand.
[0059] According to an embodiment of the present invention, the ligand comprises at least one N-acetyl-galactosamine.
[0060] According to an embodiment of the present invention, the ligand is a GalNAC compound.
[0061] According to an embodiment of the present invention, the GalNAC compound includes at least one of L96 or its isomers (such as stereoisomers, etc.), DAW4007-4 or its isomers (such as stereoisomers, etc.).
[0062] According to an embodiment of the present invention, the conjugate has the following structure or one of its isomers (such as stereoisomers):
[0063]
[0064] Wherein, A is the siRNA described in the present invention.
[0065] According to an embodiment of the present invention, A is a siRNA having a sense strand of the nucleotide sequence shown in SEQ ID NO: 312 and an antisense strand of the nucleotide sequence shown in SEQ ID NO: 328. In some embodiments of the present invention, A is specifically siRNA ID NO: 163: SS (5'-3') gs-gs-uu-Uf-u-Uf-Cf-Uf-ugu–uga–caaa (SEQ ID NO 312), AS (5'-3') us-Ufs-ugu-Cf-a-Af-Cf-aaga-Af-a-Af-ac-cs-cs-c (SEQ ID NO 328), SS represents the sense strand, and AS represents the antisense strand.
[0066] In another aspect of the present invention, the present invention provides a pharmaceutical composition, which comprises: the aforementioned siRNA or the aforementioned siRNA conjugate of the present invention. As can be seen from the above, the aforementioned siRNA and siRNA conjugate can degrade the mRNA of hepatitis B virus and inhibit the expression and replication of HBV. Therefore, the pharmaceutical composition of the present invention can effectively prevent and / or treat related diseases caused by HBV.
[0067] According to an embodiment of the present invention, the pharmaceutical composition further includes: a pharmaceutically acceptable carrier or excipient.
[0068] In another aspect of the present invention, the present invention provides a use of the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to inhibit the expression or activity of the hepatitis B virus gene.
[0069] In another aspect of the present invention, the present invention provides a use of the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to prevent and / or treat related diseases caused by hepatitis B virus.
[0070] According to an embodiment of the present invention, the related diseases caused by the hepatitis B virus include acute hepatitis B, acute fulminant hepatitis B, chronic hepatitis B, end-stage liver disease, liver fibrosis, cirrhosis and liver cancer.
[0071] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0073] Figure 1 This is the gel electrophoresis diagram of Example 2 of the present invention.
[0074] Figure 2 is the content of serum HBsAg in each group of AAV / HBV mice injected with different siRNA conjugates in Example 3 of the present invention (wherein, Figure 2 In the figure, 168 represents siRNA conjugate 168 (ie, siRNA ID NO: 168), and 169 represents siRNA conjugate 169 (ie, siRNA ID NO: 169).
[0075] Figure 3 is the content of serum HBsAg in each group of HBV-Tg mice injected with different siRNA conjugates in Example 3 of the present invention (wherein, Figure 3 In the figure, 168 represents siRNA conjugate 168 (ie, siRNA ID NO: 168), and 170 represents siRNA conjugate 170 (ie, siRNA ID NO: 170).
[0076] Detailed description of the invention
[0077] Definitions and general terms
[0078] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0079] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0080] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.
[0081] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0082] As used herein, the term "small interfering RNA (siRNA)" is a double-stranded RNA of 17 to 25 nucleotides in length, comprising a sense strand and an antisense strand. siRNA mediates targeted cleavage of RNA transcripts in the RISC pathway by forming an RNA-induced silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and into proteins. For example, siRNA can regulate (e.g., inhibit) the expression of hepatitis B virus in cells.
[0083] In this article, the term "antisense strand (or guide strand)" includes a region that is substantially complementary to a target sequence, such as the mRNA of hepatitis B virus. "Sense strand (or follower strand)" refers to an iRNA strand that contains a region that is substantially complementary to the antisense strand. The term "substantially complementary" refers to complete complementarity or at least partial complementarity, for example, the antisense strand is completely complementary to the target sequence or at least partially complementary. In the case of partial complementarity, mismatches can exist in the interior or terminal regions of the molecule, wherein the most tolerated mismatches exist in the terminal regions, for example, within 5, 4, 3 or 2 nucleotides at the 5'- and / or 3'-end of the iRNA.
[0084] It should be noted that "at least part of the antisense strand is substantially complementary to the mRNA" means that the antisense strand has a polynucleotide that is substantially complementary to a continuous portion of the mRNA of interest (e.g., the mRNA encoding the hepatitis B virus). Alternatively, if a polynucleotide is substantially non-interruptedly complementary to a portion of the mRNA encoding the hepatitis B virus, the antisense strand is complementary to at least a portion of the mRNA of the hepatitis B virus.
[0085] As used herein, the term "target sequence" refers to a continuous portion of a nucleotide sequence of an mRNA molecule formed during transcription of a gene encoding hepatitis B virus, including mRNA that is an RNA processing product of a primary transcription product.
[0086] In this article, the term "inhibiting the expression of hepatitis B virus genes" includes any level of inhibition of hepatitis B virus (abbreviated as HBV) genes, for example, at least partial inhibition of hepatitis B virus gene expression, such as inhibition of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%. Wherein, the expression of hepatitis B virus genes can be evaluated based on the level of any variable related to the expression of hepatitis B virus genes, for example, the mRNA level of hepatitis B virus or the level of hepatitis B virus protein. Inhibition can be evaluated by a reduction in the absolute or relative level of one or more of these variables compared to a control level. A control level can be any type of control level utilized in the art, e.g., a baseline level before administration, or a level measured from a similar subject, cell or sample that has never been treated or treated with a control (e.g., a control with only a buffer or a control without an active agent).
[0087] In this article, "pharmaceutical composition" can refer to a composition used for the treatment of a disease, and can also be used for in vitro culture experiments of cells. When used for the treatment of a disease, the term "pharmaceutical composition" generally refers to a unit dosage form, and can be prepared by any of the methods well known in the pharmaceutical field. All methods include the step of combining the active ingredient with an excipient that constitutes one or more accessory ingredients. Typically, the composition is prepared by uniformly and fully combining the active siRNA with a liquid excipient, a finely divided solid excipient, or both.
[0088] In this article, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, the "pharmaceutically acceptable" of the present invention refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeias for use in animals, particularly humans.
[0089] In this article, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a specific target dosage form. Except for any conventional excipients that are incompatible with the siRNA of the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present invention.
[0090] In addition to any conventional excipients, to the extent that they are incompatible with the siRNA of the present invention, such as producing any adverse biological effects or interacting in a deleterious manner with any other components of the pharmaceutically acceptable composition, their use is also contemplated by the present invention.
[0091] Pharmaceutical compositions of the present disclosure include preparations suitable for parenteral administration. Preparations can be conveniently present in unit dosage form and can be prepared by any method known in the pharmaceutical field. The amount of active ingredient that can be combined with auxiliary materials to prepare a single dose form is generally the amount of siRNA that produces a therapeutic effect. Generally speaking, in units of one percent, the amount is about 1% to about 99% active ingredient, preferably about 5% to about 70%, and most preferably about 10% to about 30%.
[0092] As used herein, the term "treatment" refers to the use of drugs to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any use of a drug or siRNA to treat, cure, alleviate, improve, reduce or inhibit a disease in an individual, including but not limited to administering a drug containing the siRNA or siRNA conjugate described herein to an individual in need. Detailed description of siRNA, siRNA conjugates, compositions and uses of the present invention
[0093] The present invention provides a siRNA, a siRNA conjugate, a pharmaceutical composition and pharmaceutical uses thereof, which will be described in detail below.
[0094] The siRA, siRNA conjugates or pharmaceutical compositions thereof of the present invention can be effectively used to prevent and / or treat diseases related to hepatitis B virus.
[0095] In one aspect of the present invention, the present invention provides an siRNA, wherein each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA includes a sense strand and an antisense strand, wherein the antisense strand has a complementary region of at least partial base pairing with the sense strand; wherein the sense strand includes one of the nucleotide sequences shown in SEQ ID NO:1 to SEQ ID NO:150, or has a difference of no more than 5 nucleotides therefrom; and the antisense strand includes one of the nucleotide sequences shown in SEQ ID NO:151 to SEQ ID NO:300, or has a difference of no more than 5 nucleotides therefrom. The inventors experimentally designed that the above-mentioned suitable small interfering RNA (siRNA) forms a silencing complex (RNA-induced silencing complex, RISC), and complementarily pairs with the sequence of the mRNA of the target gene (hepatitis B virus, referred to as hepatitis B virus, HBV), thereby degrading the mRNA of the hepatitis B virus, thereby inhibiting the expression and replication of HBV, and can effectively prevent and / or treat related diseases caused by HBV.
[0096] In the present invention, the "difference is no more than 5 nucleotides" or "has no more than 5 nucleotide differences" means that compared with the target nucleotide sequence, there may be 1, 2, 3, 4 or 5 nucleotide differences, and the difference includes but is not limited to nucleotide deletion, nucleotide insertion (which can be inserted into the 3' end, 5' end or between any two nucleotides of the nucleotide sequence), nucleotide replacement, etc. For example, "the sense strand includes one of the nucleotide sequences shown in SEQ ID NO: 1 to SEQ ID NO: 150, or has no more than 5 nucleotide differences from it" means one of the nucleotide sequences shown in SEQ ID NO: 1 to SEQ ID NO: 150, that is, "the target sequence".
[0097] In some optional embodiments of the present invention, the above siRNA may further include at least one of the following additional technical features:
[0098] In some embodiments, the antisense strand has a region of complementarity with at least 85%, or at least 90%, or at least 95% base pairing with the sense strand.
[0099] In some optional embodiments of the present invention, the positive strand comprises one of the following nucleotide sequences, or a difference therefrom of no more than 5 nucleotides: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:58, SEQ ID NO:69, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127 NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:140, SEQ ID NO:148 and SEQ ID NO:150;and / or the antisense strand comprises one of the following nucleotide sequences, or differs therefrom by no more than 5 nucleotides: SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 196, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 208, SEQ ID NO: 219, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:290, SEQ ID NO:298 and SEQ ID NO:300. ;
[0100] In some optional embodiments of the present invention, the sense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:40, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:129 and SEQ ID NO:130; and / or the antisense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO:162, SEQ ID NO:170, SEQ ID NO:190, SEQ ID NO:243, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275 NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:279 and SEQ ID NO:280.
[0101] In some optional embodiments of the present invention, the siRNA includes one of the following: a sense strand having a nucleotide sequence as shown in SEQ ID NO: 12 or a nucleotide sequence that differs from it by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 162 or a nucleotide sequence that differs from it by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO: 20 or a nucleotide sequence that differs from it by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 170 or a nucleotide sequence that differs from it by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO: 40 or a nucleotide sequence that differs from it by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 190 or a nucleotide sequence that differs from it by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO: 93 or a nucleotide sequence that differs from it by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 243 or a nucleotide sequence that differs from it by no more than 5 nucleotides; NO:97 or a sense strand of a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO:247 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO:98 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO:248 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO:99 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO:249 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO:115 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO:265 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO:116 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO:267 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides. The antisense strand of the nucleotide sequence shown in NO:266, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; the sense strand having the nucleotide sequence shown in SEQ ID NO:121, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and the antisense strand having the nucleotide sequence shown in SEQ ID NO:271, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides;A sense strand having a nucleotide sequence as shown in SEQ ID NO: 123, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 273, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO: 124, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 274, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO: 125, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 275, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; a sense strand having a nucleotide sequence as shown in SEQ ID NO: 129, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 279, or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; The sense strand of the nucleotide sequence shown in NO:130 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and the antisense strand of the nucleotide sequence shown in SEQ ID NO:280 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides. ;
[0102] In some optional embodiments of the present invention, the sense strand comprises 5'-GGUUUUUCUUGUUGACAAA-3' (SEQ ID NO: 330), and the antisense strand comprises 5'-UUUGUCAACAAGAAAAACCCC-3' (SEQ ID NO: 190).
[0103] In some optional embodiments of the present invention, the sense strand and / or antisense strand comprises a 3' overhang and / or a 5' overhang, and the 3' overhang or the 5' overhang comprises at least one nucleotide.
[0104] In some optional embodiments of the present invention, the sense strand and / or antisense strand comprises a 3' overhang.
[0105] In some optional embodiments of the present invention, the sense strand and / or antisense strand comprises a 3' overhang, and the 3' overhang comprises 2 nucleotides.
[0106] As used herein, the term "overhang" refers to at least one unpaired nucleotide that protrudes from the siRNA double helix structure. For example, when the 3' end of one strand in the sense strand and / or the antisense strand exceeds the 5' end of the other strand, or when the 5' end of one strand in the sense strand and / or the antisense strand exceeds the 3' end of the other strand, there is a nucleotide overhang. The overhang may contain at least one nucleotide, at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more nucleotides. The nucleotide overhang may contain or may be composed of nucleotide / nucleoside analogs, including deoxynucleotides / nucleosides. The overhang may be located on the sense strand, the antisense strand, or any combination thereof. In addition, the nucleotides of the overhang may appear at the 5'-end, the 3'-end, or both ends of the antisense or sense strand.
[0107] In some optional embodiments of the present invention, the sense strand and / or the antisense strand includes at least one modified nucleotide, and the modified nucleotide is independently and optionally selected from at least one of the following: non-natural base nucleotides, deoxynucleotides, 2'-fluoro-modified nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl-modified nucleotides, 2'-alkyl-modified nucleotides, 2'-O-alkyl-modified nucleotides, 2'-methoxyethyl-modified nucleotides, locked nucleotides, configuration-restricted nucleotides, 2'-allyl-modified nucleotides, abasic nucleotides, morpholino nucleotides, tetrahydropyran-modified nucleotides, 1,5-anhydrohexitol-modified nucleotides, cyclohexenyl-modified nucleotides, PEG-modified nucleotides, 5'-phosphoramidate-modified nucleotides, 5'-phosphorothioate-modified nucleotides, 5'-methylphosphonate-modified nucleotides, 5'-phosphate mimetic-modified nucleotides, and 5'-methylated cytosine-modified nucleotides.
[0108] It should be noted that when a modified nucleotide is selected from a 2'-alkyl modified nucleotide and a 5'-phosphorothioate modified nucleotide, it means that the modified nucleotide has both a 2'-alkyl modification and a 5'-phosphorothioate modification.
[0109] As is known to those skilled in the art, a ribonucleotide molecule is composed of phosphate, ribose and base. In this article, a "modified nucleotide" refers to a nucleotide that has a different group attached to a different C atom on the ribose, a change in the phosphate group, or a lack of a base compared to an A, U, C or G nucleotide. In this article, "modified nucleotide" and "modified nucleotide" are synonymous.
[0110] In some optional embodiments of the present invention, the modified nucleotide has one or more modifications.
[0111] In some optional embodiments of the present invention, the modifications include 2'-fluoro modification, 2'-amino modification, 2'-O-allyl modification, 2'-alkyl modification, 2'-O-alkyl modification, 2'-methoxyethyl modification, 2'-allyl modification, tetrahydropyran modification, 1,5-anhydrohexitol modification, cyclohexenyl modification, PEG modification, 5'-phosphoramidate modification, 5'-phosphorothioate modification, 5'-methylphosphonate modification, 5'-phosphate mimetic modification and 5'-methylated cytosine modification.
[0112] In some optional embodiments of the present invention, the modification includes at least one of a 2'-methoxy modification, a 2'-fluoro modification, and a 5'-phosphorothioate modification.
[0113] In this article, "deoxynucleotide" refers to a nucleotide in which the hydroxyl group in the pentose of the nucleotide is deoxygenated, and the deoxygenation position can be 2'-OH or 3'-OH.
[0114] In some optional embodiments of the present invention, the deoxynucleotides include 3'-deoxy modified nucleotides and 2'-deoxy modified nucleotides.
[0115] Herein, "2'-deoxy modification" refers to the deoxygenation of the hydroxyl group (2'-OH) in the pentose nucleotide to hydrogen (2'-H), and "3'-deoxy modification" refers to the deoxygenation of the hydroxyl group (3'-OH) in the pentose nucleotide to hydrogen (3'-H).
[0116] In this article, "2'-X modification" refers to the replacement of the hydroxyl group (2'-OH) in the nucleotide pentose by X (2'-X). For example, "2'-fluoro modification" refers to the replacement of the hydroxyl group (2'-OH) in the nucleotide pentose by fluorine (2'-F), "2'-amino modification" refers to the replacement of the hydroxyl group (2'-OH) in the nucleotide pentose by fluorine (2'-NH2), "2'-O-allyl modification" refers to the replacement of the hydroxyl group (2'-OH) in the nucleotide pentose by allyloxy (2'-OCH2CH=CH2), "2'-alkyl modification" refers to the replacement of the hydroxyl group (2'-OH) in the nucleotide pentose by alkyl (2'-alkyl), and "2'-O-alkyl modification" refers to the replacement of the hydroxyl group (2'-OH) in the nucleotide pentose by alkoxy (2'-alkoxy).
[0117] As used herein, "locked nucleotide" refers to a nucleotide obtained by modifying the 2' and 4' carbons of the pentose of a nucleotide to link them together.
[0118] In this article, "5'-X modification" refers to the replacement of phosphate (5'-PO(OH)2) in nucleotide pentose by X (5'-X). For example, "5'-phosphoramidate modification" refers to the replacement of phosphate (5'-PO(OH)2) in nucleotide pentose by phosphoramidate, "5'-phosphorothioate modification" refers to the replacement of phosphate (5'-PO(OH)2) in nucleotide pentose by phosphorothioate, "5'-methylphosphonate modification" refers to the replacement of phosphate (5'-PO(OH)2) in nucleotide pentose by methylphosphonate, and "5'-phosphate mimetic modification" refers to the replacement of phosphate (5'-PO(OH)2) in nucleotide pentose by phosphate mimetic.
[0119] As used herein, "2'-methoxy modification" refers to the replacement of the hydroxyl group (2'-OH) in the pentose of a nucleotide with a methoxy group (2'-OCH3).
[0120] As used herein, "2'-methoxyethyl modification" refers to the replacement of the hydroxyl group (2'-OH) in the pentose of a nucleotide with a methoxyethyl group (2'-OCH2CH2OCH3).
[0121] As used herein, "5'-methylated cytosine modification" refers to methylation at the 5th carbon atom of cytosine.
[0122] In some optional embodiments of the present invention, the sense strand and / or the antisense strand comprises at least one modified nucleotide, and the modified nucleotide is independently and optionally selected from at least one of a 5'-phosphorothioate-modified nucleotide, a 5'-methylated cytosine-modified nucleotide, a 2'-methoxy-modified nucleotide, a 2'-methoxyethyl-modified nucleotide, a 2'-fluoro-modified nucleotide, a 2'-amino-modified nucleotide and a 2'-deoxy-modified nucleotide.
[0123] In some optional embodiments of the present invention, the sense strand and / or the antisense strand comprises at least one modified nucleotide, and the modified nucleotide is independently and optionally selected from at least one of a 2'-methoxy-modified nucleotide, a 2'-fluoro-modified nucleotide and a 5'-phosphorothioate-modified nucleotide.
[0124] In some embodiments of the present invention, the sense strand comprises 5'-GGUUUUUCUUGUUGACAAA-3' (SEQ ID NO: 330), and the length of the sense strand is no more than 21 nucleotides, the antisense strand comprises 5'-UUUGUCAACAAGAAAAACCCC-3' (SEQ ID NO: 190), and the length of the antisense strand is no more than 23 nucleotides, and each nucleotide in the sense strand and the reaction strand is a modified nucleotide.
[0125] In some embodiments of the present invention, in the sense strand and / or the antisense strand, the 2'-fluoro-modified nucleotides are present at the following positions:
[0126] The nucleotides at the 5' end of the sense strand are the 5th, 7th, 8th and 9th nucleotides of the starting point; and / or
[0127] The nucleotides at the 5' end of the antisense strand are the 2nd, 6th, 8th, 9th, 14th and 16th nucleotides of the starting point.
[0128] In some embodiments of the present invention, in the sense strand and / or the antisense strand, 5'-phosphorothioate-modified nucleotides are present at the following positions:
[0129] The nucleotides at the 5' end of the sense strand are the first and second 5'-phosphorothioate modified nucleotides at the starting point; and / or
[0130] The nucleotides at the 5' end of the antisense strand are the first and second nucleotides of the starting point, and / or the nucleotides at the 3' end of the antisense strand are the second and third nucleotides of the starting point.
[0131] In some embodiments of the present invention, in the sense strand and / or the antisense strand, the 2'-methoxy modified nucleotides are present at the following positions:
[0132] The nucleotides at the 5' end of the sense strand are the 1st, 2nd, 3rd, 4th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th and 19th nucleotides of the starting point; and / or
[0133] The nucleotide at the 5' end of the antisense strand is the 1st, 3rd, 4th, 5th, 7th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th, 20th or 21st nucleotide of the starting point.
[0134] In some embodiments of the present invention, the nucleotides at the 5' end of the sense strand are 2'-methoxy modified nucleotides at positions 1, 2, 3, 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19 from the starting point.
[0135] In some embodiments of the present invention, the nucleotide at the 5' end of the antisense strand is a 2'-methoxy modified nucleotide at the 1st, 3rd, 4th, 5th, 7th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th, 20th or 21st position of the starting point.
[0136] In some embodiments of the present invention, the nucleotides at the 5' end of the sense strand are 2'-fluoro-modified nucleotides at positions 5, 7, 8 and 9 of the starting point.
[0137] In some embodiments of the present invention, the nucleotides at the 5' end of the sense strand are 2'-fluoro-modified nucleotides at the first and second positions of the starting point.
[0138] In some embodiments of the present invention, the nucleotides at the 5' end of the antisense strand are nucleotides modified with a 5'-phosphorothioate group at the 2nd, 6th, 8th, 9th, 14th and 16th positions from the starting point.
[0139] In some embodiments of the present invention, the nucleotides at the 5' end of the antisense strand are the 1st and 2nd nucleotides of the starting point, and / or the nucleotides at the 3' end of the antisense strand are the 2nd and 3rd nucleotides of the starting point are 5'-phosphorothioate modified nucleotides.
[0140] In some optional embodiments of the present invention, the number of modified nucleotides in the sense strand and / or the antisense strand may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21.
[0141] In some optional embodiments of the present invention, all nucleotides in the sense strand and / or the antisense strand are modified nucleotides, and the modified nucleotides are independently and optionally selected from at least one of 2'-methoxy-modified nucleotides, 2'-fluoro-modified nucleotides and 5'-phosphorothioate-modified nucleotides.
[0142] Exemplarily, the nucleotide at the 5' end of the sense strand is the first nucleotide at the starting point and is a 2'-methoxy modified nucleotide and a 5'-phosphorothioate modified nucleotide, that is, the nucleotide at the 5' end of the sense strand is the first nucleotide at the starting point and has both a 2'-methoxy modification and a 5'-phosphorothioate modification.
[0143] Exemplarily, the nucleotide at the 5' end of the sense strand is the second nucleotide from the starting point and is a 2'-methoxy-modified nucleotide and a 5'-phosphorothioate-modified nucleotide.
[0144] Exemplarily, the nucleotide at the 5' end of the antisense strand is the first nucleotide at the starting point, and the nucleotide at the 3' end of the antisense strand is the second and third nucleotides at the starting point, which are both 2'-methoxy-modified nucleotides and 5'-phosphorothioate-modified nucleotides.
[0145] Exemplarily, the nucleotide at the 5' end of the antisense strand is the second nucleotide from the starting point and is a 2'-fluoro-modified nucleotide and a 5'-phosphorothioate-modified nucleotide.
[0146] In some optional embodiments of the present invention, the siRNA includes one or more of the following groups:
[0147]
[0148]
[0149] In the sense strand and the antisense strand, a, g, c and u are 2'-O-methyl (2'-OMe) A, 2'-OMe G, 2'-OMeC and 2'-OMe U, respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U, respectively; and s indicates that the nucleotide has a 5'-phosphorothioate modification.
[0150] In some optional embodiments of the present invention, the siRNA comprises one of the following:
[0151]
[0152] In the sense strand and the antisense strand, a, g, c and u are 2'-O-methyl (2'-OMe) A, 2'-OMe G, 2'-OMeC and 2'-OMe U, respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U, respectively; and s indicates that the nucleotide has a 5'-phosphorothioate modification.
[0153] In another aspect of the present invention, the present invention provides an siRNA conjugate. According to an embodiment of the present invention, the siRNA conjugate comprises: the aforementioned siRNA; a ligand, wherein the siRNA is connected to the ligand. The siRNA conjugate of the present invention can further improve the degradation of hepatitis B virus mRNA by adding a ligand, and can effectively prevent and / or treat related diseases caused by HBV.
[0154] As used herein, the term "ligand" or "carrier" refers to a class of substances that have the ability to alter the distribution, targeting or lifespan of siRNA, for example, the ligand provides an enhanced affinity for a selected target (e.g., a molecule, a cell or a cell type, a compartment (e.g., a cell or an organ compartment, a body tissue, an organ or a region)) compared to a species in which the ligand is not present. The ligand may be a natural protein (e.g., human serum albumin (HSA)), a carbohydrate (e.g., dextran and chitosan, etc.) or a lipid; it may also be a recombinant or synthetic molecule, such as a synthetic polymer. Preferably, the ligand does not participate in the pairing of the sense and antisense strands in the siRNA.
[0155] In some optional embodiments of the present invention, the siRNA conjugate of the present invention may further include at least one of the following technical features:
[0156] In some optional embodiments of the present invention, the ligand is linked to the sense strand and / or the antisense strand.
[0157] In some optional embodiments of the present invention, the ligand is linked to the sense strand and / or antisense strand via a phosphorothioate bond or a phosphate bond.
[0158] In some optional embodiments of the present invention, the ligand is connected to the 5' end or 3' end of the sense strand; or the ligand is connected to the 5' end or 3' end of the antisense strand.
[0159] In some optional embodiments of the present invention, the ligand comprises at least one N-acetyl-galactosamine.
[0160] In some optional embodiments of the present invention, the ligand is a GalNAC compound.
[0161] In some optional embodiments of the present invention, the GalNAC compound includes at least one of the following: L96 or its isomers (such as stereoisomers, etc.), DAW4007-4 or its isomers (such as stereoisomers, etc.).
[0162] The structure of L96 described in the present invention is
[0163]
[0164] The structure of DAW4007-4 described in the present invention is
[0165]
[0166] According to an embodiment of the present invention, the conjugate has the following structure or one of its isomers (such as stereoisomers):
[0167]
[0168]
[0169] Wherein, A is the siRNA described in the present invention.
[0170] According to an embodiment of the present invention, A is a siRNA having a sense strand of the nucleotide sequence shown in SEQ ID NO: 312 and an antisense strand of the nucleotide sequence shown in SEQ ID NO: 328. Specifically:
[0171] siRNA ID NO:163:
[0172] SS(5'-3')gs-gs-uu-Uf-u-Uf-Cf-Uf-ugu–uga–caaa (SEQ ID NO 312),
[0173] AS(5'-3')us-Ufs-ugu-Cf-a-Af-Cf-aaga-Af-a-Af-ac-cs-cs-c (SEQ IDNO 328),
[0174] SS represents the sense strand and AS represents the antisense strand.
[0175] In some embodiments, the siRNA conjugate of the invention is one of the following siRNA ID NO: 169 and siRNA ID NO: 170:
[0176] siRNA ID NO:169:
[0177] SS(5'-3')gs-gs-uu-Uf-u-Uf-Cf-Uf-ugu–uga–caaa-L96,
[0178] AS(5'-3')us-Ufs-ugu-Cf-a-Af-Cf-aaga-Af-a-Af-ac-cs-cs-c, or
[0179] siRNA ID NO:170:
[0180] SS(5'-3'):gs-gs-uu-Uf-u-Uf-Cf-Uf-uguugacaaa-DAW40007
[0181] AS(5'-3'): us-Ufs-ugu-Cf-a-Af-Cf-aaga-Af-a-Af-ac-cs-cs-c.
[0182] Wherein, each L96 and DAW40007 is independently connected to the 3' end of the sense strand via a phosphate bond or a phosphorothioate bond.
[0183] Exemplarily, the ligand L96 is linked to the 3-terminal end of the sense strand via a phosphate bond; and the ligand DAW40007 is linked to the 3-terminal end of the sense strand via a phosphate bond.
[0184] The SS of the present invention represents the sense strand, and AS represents the antisense strand. In another aspect of the present invention, the present invention provides a use of the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition in the preparation of a drug for inhibiting the expression or activity of a hepatitis B virus gene.
[0185] In another aspect of the present invention, the present invention provides a use of the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to prevent and / or treat related diseases caused by hepatitis B virus.
[0186] In some optional embodiments of the present invention, the related diseases caused by the hepatitis B virus include acute hepatitis B, acute fulminant hepatitis B, chronic hepatitis B, end-stage liver disease, liver fibrosis, cirrhosis and liver cancer.
[0187] Preparation, administration and disease treatment method of siRNA drug of the present invention
[0188] The siRNA drug of the present invention includes siRNA, siRNA conjugates or a combination thereof.
[0189] In another aspect of the present invention, the present invention proposes a method for inhibiting the expression or activity of hepatitis B virus genes. According to an embodiment of the present invention, the method comprises: contacting the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition with cells. As mentioned above, the aforementioned siRNA and siRNA conjugate can degrade the mRNA of hepatitis B virus and inhibit the expression and replication of HBV. Therefore, the method of the present invention can be used to inhibit the expression or activity of hepatitis B virus genes. For example, the expression or activity of hepatitis B virus genes can be inhibited in animals; or the expression or activity of hepatitis B virus genes can be inhibited for non-disease treatment purposes, such as inhibiting the expression or activity of hepatitis B virus genes in vitro for subsequent research.
[0190] In another aspect of the present invention, the present invention provides a method for preventing and / or treating hepatitis B virus-induced diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the aforementioned siRNA, the aforementioned siRNA conjugate, or the aforementioned pharmaceutical composition to a subject. According to an embodiment of the present invention, the method can effectively prevent and / or treat diseases related to hepatitis B virus-induced diseases.
[0191] The effective amount of the siRNA, siRNA conjugate or pharmaceutical composition of the present invention may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, for example, four times a day, three times a day, twice a day, once a day, or once every other day, or several doses administered daily may be proportionally reduced.
[0192] The drug can be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, including intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration and topical administration (including buccal administration and sublingual administration), preferably intravenous injection.
[0193] In some optional embodiments of the present invention, the related diseases caused by the hepatitis B virus include acute hepatitis B, acute fulminant hepatitis B, chronic hepatitis B, end-stage liver disease, liver fibrosis, cirrhosis and liver cancer. DETAILED DESCRIPTION
[0194] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0195] Synthesis of ligand (compound DAW40007-3)
[0196]
[0197]
[0198] Step 1: Synthesis of compound 2-2
[0199] Compound 2-1 (2.50 g, 28.05 mmol) and triethylamine (7.8 mL, 56.1 mmol) were dissolved in DCM (120 mL), and benzyl chloroformate (9.57 g, 56.1 mmol) was added dropwise at 0°C. After the addition, the reaction mixture was heated to room temperature and stirred for 20 h, and saturated ammonium chloride solution (50 mL) was added for dilution, the liquids were separated, the aqueous phase was discarded, the organic phase was concentrated, and the residue was purified by silica gel column chromatography (MeOH / DCM (V / V) = 1 / 30) to obtain white solid compound 2-2 (2.96 g, 47.2%).
[0200] MS (ESI, pos.ion) m / z: 224.2 [M+H] + ;
[0201] 1 H NMR(400MHz, CDCl3)δ7.37(d,J=4.2Hz,5H),5.11(s,2H),5.00(s,1H),4.19–4.14(m,1H),3.70–3.64(m, 2H), 3.24 (t, J=6.4Hz, 2H), 3.15 (q, J=4.6Hz, 1H), 1.90 (dq, J=14.2, 5.0, 4.3Hz, 2H), 1.77–1.71 (m, 1H).
[0202] Step 2: Synthesis of compound 2-4
[0203] Compound 2-3 (1.5 g, 4.56 mmol) and compound 2-2 (1.22 g, 5.47 mmol) were dissolved in 1,2-dichloroethane (30 mL), and 3A molecular sieves (2.0 g) were added and stirred at room temperature for 10 min. TMSOTf (0.51 g, 2.28 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction solution was poured into a saturated sodium bicarbonate solution (100 mL), then extracted with DCM (100 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA (V / V) = 2 / 1 to 0 / 1) to obtain a light brown oil compound 2-4 (1.8 g, 71.51%). MS (ESI, pos.ion) m / z: 553.3 [M+H] + .
[0204] Step 3: Synthesis of Compound 2-5
[0205] Compound 2-4 (0.57 g, 1.03 mmol) and palladium carbon (0.11 g, 0.1 mmol, 10%) were added to THF (10 mL), and then TFA (0.12 g, 1.03 mmol) was added, followed by hydrogen replacement three times, and then stirred at room temperature for 19 h in a hydrogen atmosphere. After the reaction was completed, diatomaceous earth was filtered, and the solvent was evaporated under reduced pressure to obtain a light brown oily compound 2-5 (0.55 g, 100.32%). MS (ESI, pos.ion) m / z: 419.3 [M-TFA+H] + .
[0206] Step 4: Synthesis of Compound 2-7
[0207] Compound 2-6 (0.46 g, 2.29 mmol, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and compound 2-5 (1.16 g, 2.18 mmol) were dissolved in DCM (30 mL), and HOBT (0.46 g, 3.44 mmol), HBTU (1.30 g, 3.44 mmol) and DIPEA (2.66 mL, 16.03 mmol) were added in sequence, and the reaction mixture was reacted at room temperature for 16 h. After the reaction, water (20 mL) and DCM (50 mL × 2) were added in sequence, and the organic phase was washed with saturated sodium bicarbonate solution (30 mL) and saturated brine (20 mL) in sequence, and the solvent was evaporated under reduced pressure. The residue was separated and purified by silica gel column chromatography (MeOH / EA (v / v) = 1 / 20) to obtain a white solid 2-7 (1.0 g, yield 72.7%).
[0208] MS (ESI, pos.ion) m / z: 602.3 [M+H] + ;
[0209] 1 H NMR (400MHz, CD3OD) δ5.39–5.33(m,1H),5.07(dd,J=11.2,3.4Hz,1H),4.58(d,J= 8.4Hz,1H),4.21–4.09(m,3H),4.04(t,J=6.7Hz,1H),3.89(dt,J=10.4,5.1Hz,1H ),3.60–3.50(m,1H),3.30–3.13(m,2H),2.16(s,3H),2.04(s,3H),1.97(s,3H),1 .94(s,3H),1.67–1.56(m,4H),1.48(s,9H),1.41–1.37(m,2H),1.02–0.98(m,2H).
[0210] Step 5: Synthesis of Compound 2-8
[0211] Compound 2-7 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), and then TFA (0.87 mL, 11.7 mmol) was added. The reaction mixture was stirred at 25 °C for 16 h, and the solvent was concentrated to give brown oily compound 2-8 (0.74 g, 103.1%).
[0212] MS (ESI, pos.ion) m / z: 502.2 [M+H] + ;
[0213] 1 H NMR (400MHz, CD3OD) δ5.36 (d, J=3.3Hz, 1H), 5.08 (dd, J=11.3, 3.3Hz, 1H), 4.5 8(d,J=8.4Hz,1H),4.16–4.10(m,3H),4.08–4.02(m,1H),3.92–3.85(m,1H),3 .58–3.50(m,1H),3.26–3.20(m,2H),2.16(s,3H),2.04(d,J=5.2Hz,6H),1.98 (s,3H),1.97(s,3H),1.61–1.56(m,4H),1.54–1.52(m,2H),1.42–1.38(m,2H).
[0214] Step 6: Synthesis of Compound 2-10
[0215] Compound 2-9 (0.19 g, 0.30 mmol) and compound 2-8 (0.50 g, 0.99 mmol) were dissolved in DCM (30 mL), and then HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol) and DIPEA (0.5 mL, 3.0 mmol) were added in sequence, and the reaction mixture was stirred at 30 ° C for 3 h. After the reaction was completed, water (20 mL) was added to quench the reaction, and then extracted with DCM (100 mL × 2), and the organic phases were combined, and the organic phases were washed with saturated sodium bicarbonate solution (40 mL) and saturated sodium chloride solution (40 mL) in sequence, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was separated and purified by silica gel column chromatography (DCM / MeOH (v / v) = 10 / 1) to obtain white solid compound 2-10 (0.23 g, yield 37%).
[0216] MS(ESI,pos.ion)m / z:1046.3[M / 2+H] + ;
[0217] 1H NMR (400MHz, CD3OD) δ7.78(t,J=5.8Hz,2H),7.38–7.36(m,3H),5.36(d,J=3.4Hz,3H),5.13(s,2H),5.08(dd,J=11.2, 3.4Hz,3H),4.58(d,J=8.4Hz,3H),4.21–4.08(m,9H),4.04(t,J=6.7Hz,3H),3.93–3.82(m,3H),3.73–3.66(m,12H),3. 60–3.52(m,3H),3.29–3.18(m,6H),2.52(t,J=6.0Hz,6H),2.38(t,J=7.4Hz,2H),2.20(t,J=7.7Hz,2H),2.16(s,9H), 2.04(s,9H),1.97(s,9H),1.95(s,9H),1.62–1.56(m,12H),1.50–1.42(m,6H),1.35–1.27(m,16H),1.04–0.97(m,6H).
[0218] Step 7: Synthesis of Compound 2-11
[0219] Compound 2-10 (0.20 g, 0.094 mmol) was dissolved in methanol (10 mL), and then Pd / C (10 mg, 10%) was added, and hydrogen was replaced three times. The reaction mixture was stirred at room temperature for 11 h in a hydrogen atmosphere. After the reaction was completed, the reaction mixture was filtered through diatomaceous earth, and the obtained filtrate was evaporated under reduced pressure to dry the solvent to obtain a white solid compound 2-11 (0.19 g, 100%).
[0220] MS(ESI,pos.ion)m / z:1001.1[M / 2+H] + .
[0221] Step 8: Synthesis of compound DAW40007-1
[0222] Compound 2-11 (0.28 g, 0.14 mmol) was dissolved in DCM (20 mL), and HOBT (0.038 g, 0.28 mmol), HBTU (0.080 g, 0.21 mmol), DIPEA (0.054 g, 0.42 mmol) and compound 13 (0.068 g, 0.16 mmol) were added in sequence. The reaction mixture was stirred at room temperature for 13 h. After the reaction was completed, water (10 mL) was added to quench the reaction, and the mixture was extracted with DCM (20 mL). The organic phase was washed with saturated sodium bicarbonate solution (10 mL) and the mixture was heated to 40 ℃. The solvent was evaporated, and the obtained residue was dissolved in acetonitrile (10 mL), and separated by reverse phase preparative column (acetonitrile / water solution (v / v) = 43% to 60%, 50 min). Salt was added to the solution containing the product after preparative separation to saturate the solution, and the organic phase was separated. The aqueous phase was extracted with acetonitrile (100 mL×2), and the organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Acetonitrile (30 mL) was added to the residue, and it was dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow solid compound DAW40007-1 (0.080 g, yield 24%).
[0223] MS(ESI,neg.ion)m / z:2400.18[MH] - ;
[0224] 1H NMR (400MHz, DMSO-d6) δ8.31 (s, 3H), 7.81 (d, J = 9.2Hz, 3H), 7.57 (t, J = 6.0 Hz,3H),7.35–7.26(m,4H),7.20(td,J=8.9,3.0Hz,5H),6.95(s,1H),6.88( ddd,J=8.8,5.8,2.2Hz,4H),5.22(d,J=3.4Hz,3H),4.97(dd,J=11.2,3.5H z,4H),4.49(d,J=8.5Hz,3H),4.40(d,J=4.8Hz,1H),4.15(s,1H),4.07–4.0 0(m,9H),3.88(dt,J=11.2,8.8Hz,3H),3.74(s,9H),3.59–3.48(m,12H),3 .17(dd,J=8.8,5.0Hz,1H),3.10–2.95(m,8H),2.35(t,J=6.3Hz,6H),2.10( s,9H),2.08(s,3H),2.04(d,J=4.7Hz,2H),2.00(s,9H),1.89(s,9H),1.78( s,9H),1.40(d,J=12.2Hz,17H),1.31–1.16(m,18H),0.79(q,J=3.2Hz,6H).
[0225] Step 9: Synthesis of compound DAW40007-2
[0226] Compound DAW40007-1 (0.080 g, 0.033 mmol) was dissolved in DCM (10 mL), and DIPEA (0.029 mL, 0.17 mmol), succinic anhydride (0.008 g, 0.083 mmol) and DMAP (0.014 g, 0.12 mmol) were added. The mixture was stirred at 40 °C for 5 h, and succinic anhydride (10 mg) was added. After the reaction was continued for 16 h, DCM (10 mL), succinic anhydride (10 mg) and DIPEA (0.05 mL) were added. The mixture was stirred for another 9 h, and then succinic anhydride (10 mg) was added. After the reaction was continued for another 10 h, DCM (20 mL) was added for dilution, and the mixture was washed with saturated sodium bicarbonate solution (10 mL). The aqueous phase was discarded, and the organic phase was dried over anhydrous sodium sulfate. The solvent was concentrated under reduced pressure to obtain a white solid compound DAW40007-2 (0.08 g, 96.07%). MS(ESI,neg.ion)m / z:2500.12[MH] - .
[0227] Step 10: Synthesis of compound DAW40007-3
[0228] Compound DAW40007-2 (0.08 g, 0.032 mmol), HBTU (0.015 g, 0.04 mmol) and DIPEA (0.011 mL, 0.064 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. The mixture was then transferred to a solid phase synthesizer containing 0.35 g H2N-CPG (purchased from Hebei Dinaxingke) and shaken for 22.5 h. The filter cake was filtered, rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL), and dried. The obtained filter cake was diluted in 25% Ac2O / Py solution (5 mL) and stirred for 3 h. The filter cake was filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) in turn, and dried under reduced pressure to obtain a white solid DAW40007-3 (0.357 g) with a measured loading of 14.95 μmol / g. For CPG.
[0229] It is well known in the art that DAW40007-4 is the residue after chemical reaction of DAW40007-3, which is covalently bonded to Nucleic acid ligation (eg, After DAW40007-3 was connected to the positive strand of siRNA, it was deprotected (i.e., cleaved) to obtain the positive strand with DAW40007-4. )。
[0230] Synthesis of ligand L96
[0231] Ligand L96 was prepared according to the method described in patent application WO2014025805A1.
[0232] Example 1: Design and screening of siRNA
[0233] 1. siRNA design
[0234] The siRNA sequences were designed according to the HBV cDNA target sequence (GenBank Accession #U95551.1). Specifically, the Ui-Tei and Reynolds algorithms were used to design functional siRNAs targeting HBV X and HBsAg mRNAs. In silico homology analysis was further performed to obtain 150 siRNA sequences. The 150 designed siRNA sequences were synthesized by GenScript Biotech Co., Ltd., as shown in Table 1.
[0235] 2. Cell activity screening
[0236] Hepatoma cells (Hep AD38) were cultured in DMEM medium containing 10% fetal bovine serum in a 5% CO2, 37°C constant temperature incubator. When the hepatoma cells were in the logarithmic growth phase and in good condition (70% confluence), they were transfected with transfection reagent. The concentration of hepatoma cells was adjusted and 1.5×10 cells were seeded into each well of a 96-well plate. 4 The cells were transfected with different siRNAs in step 1 of this example according to the instructions of RNAiMAX transfection reagent (Invitrogen), and then incubated for 72 hours at 37°C and 5% CO2. The HBsAg expression level and cytotoxicity were detected using HBsAg Elisa kit and CCK8. The specific test results are shown in Table 1.
[0237] Table 1: Sequences of various siRNAs and their detection results
[0238]
[0239]
[0240]
[0241]
[0242] Inventors under EC 50 The above siRNAs were screened, and finally 12, 20, 40, 93, 97, 98, 99, 115, 116, 121, 123, 124, 125, 129 and 130 groups of siRNA sequences were selected for the next step of modification.
[0243] Example 2: Synthesis and screening of modified siRNA
[0244] 1. Synthesis of modified siRNA
[0245] The steps for synthesizing the sense and antisense strands of siRNA without GalNac are as follows:
[0246] The siRNA screened out in Example 1 was modified according to Table 2, and the modified siRNA was synthesized at a synthesis scale of 1 μmoL according to the standard oligonucleotide solid phase synthesis protocol. 1 μmoL of universal solid phase support CPG (purchased from Hebei Dinaxingke), commercially available 2'-methoxy monomer (purchased from Wuhu Huaren Technology) and commercially available 2'-fluoro monomer (purchased from Wuhu Huaren Technology) were weighed and dissolved in anhydrous acetonitrile solution to make the monomer degree reach 0.1M. For oligonucleotides with phosphate backbone thiolation modification, 0.1M DDTT solution (CAS No.: 1192027-04-5) was used as the thiolation reagent, 5-ethylthio-1H-tetrazole acetonitrile solution (0.25M) was used as the activator (purchased from Suzhou Kelema), 0.02M iodine pyridine / water solution was used as the oxidant, and 3% trichloroacetic acid dichloromethane solution was used as the deprotection reagent. They were placed in the reagent designated position corresponding to the KA-H8 model DNA / RNA automatic synthesizer, the synthesis program was set, and the designated oligonucleotide base sequence was entered. After checking that everything was correct, the cyclic oligonucleotide synthesis was started. The coupling time for each step was 6 minutes, and the thiolation time was 6 minutes. After automatic circulation, the oligonucleotide solid phase synthesis was completed.
[0247] The oligonucleotide containing solid support CPG obtained above was blown dry with dry argon, transferred to a 2mL EP tube, and 1.8mL of ammonia solution was added, and heated at 55°C for 5 to 18 hours. Filter, wash the filter cake with 0.5mL of water, combine the solutions, and concentrate to obtain a white or yellow colloidal solid. After reverse phase preparation and purification, concentrate the preparation solution, pass it through a gel column, and remove excess salt. The concentration of the obtained oligonucleotide is determined by a micro-ultraviolet spectrophotometer (SPECTRO stat Nano). Mass spectrometry detection and analysis are completed on the Agilent 6530LC-MSQ-Tof system. After primary scanning, the molecular weight of the nucleic acid is calculated after deconvolution.
[0248] Annealing steps:
[0249] The sense strand of the siRNA synthesized above was mixed with the antisense strand of the siRNA synthesized above in equimolar amounts, heated to 95° C., maintained at the temperature for 10 minutes, and then slowly cooled to room temperature, and then freeze-dried to obtain the target siRNA.
[0250] 2. Cell activity screening
[0251] Hepatoma cells (Hep AD38) were cultured in DMEM medium containing 10% fetal bovine serum in a 5% CO2, 37°C constant temperature incubator. When the hepatoma cells were in the logarithmic growth phase and in good condition (70% confluence), they were transfected with transfection reagent. The concentration of hepatoma cells was adjusted and 1.5×10 cells were seeded into each well of a 96-well plate. 4The cells were transfected with different siRNAs in step 1 of this example according to the instructions of RNAiMAX transfection reagent (same as in Example 1), and then incubated for 72 hours at 37°C and 5% CO2. The HBsAg expression level and cytotoxicity were detected using HBsAg Elisa kit and CCK8. The specific test results are shown in Table 1, where Top refers to the inhibition rate of each siRNA conjugate on liver cancer cells.
[0252] Table 2: siRNA modification and the inhibitory activity and toxicity test results of modified siRNA on HBV
[0253]
[0254] a, g, c and u are 2'-OMe A, 2'-OMe G, 2'-OMeC and 2'-OMe U, respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U, respectively; s indicates that the nucleotide represented by the lowercase or uppercase letter has a 5'-phosphorothioate modification, and the nucleotides not represented by s are all 5'-phosphate groups.
[0255] As shown in Table 2, the siRNA of the present application has good HBV inhibitory activity and low cytotoxicity. Compared with siRNA No. 160, siRNAs 152-155, 157, 159 and 163-167 all have better HBV inhibitory activity.
[0256] 3. Serum stability test
[0257] 10 μl of a 20 μM small interfering nucleic acid (selected from one of 152 to 167 in Table 2 of this Example) was added to a solution containing 10 μl of fetal bovine serum or human serum and 80 μl of PBS, and incubated at 37°C for a certain period of time (0 / 2 / 5 / 8 / 24 / 48 h) before sampling, wherein 10 μl of the sample was taken each time and quick-frozen in liquid nitrogen to immediately terminate the effect of serum nuclease on the small interfering nucleic acid, and then the sample was stored at -80°C for later use.
[0258] Prepare 20% polyacrylamide gel as loading buffer, mix 3 μl loading buffer with the modified siRNA sample, and perform electrophoresis at a constant current of 120 V. After electrophoresis, stain with 1×SybrGold dye (Invitrogen, Cat. 11494) for 20 minutes and then take photos. The results are shown in the attached Figure 1 (Attached Figure 1 The ID number in the table is the ID number of the modified siRNA. The results showed that the modified siRNA samples all had good serum stability.
[0259] 4. HepG2 cell evaluation of the pan-genotypic effect of modified siRNA in inhibiting HBV
[0260] 152, 153, 155, 161, 162, 163, 164, 165, 166, and 167 were further selected for pan-gene (A / B / C / D / E / F / G) investigation. Taking a 96-well plate as an example: On day 0, 3×10 hepG2 cells were plated in a 96-well plate. 4 / well, cultured in a 5% CO2, 37°C constant temperature incubator. On day 1, siRNA was transfected using RNAiMAX transfection reagent. On day 2, HBV pan-gene plasmid was transfected using lipo3000 transfection reagent. On day 5, cell supernatants were collected, HBsAg secretion expression was detected by HBsAg Elisa kit, and cytotoxicity was detected by CCK8 or CTG. The results are shown in Tables 3 and 4.
[0261] Table 3: EC of modified siRNA against different HBV genotypes 50 Test results
[0262]
[0263] Table 4: EC of modified siRNA against different HBV genotypes 50 Test results
[0264]
[0265] Example 3: Preparation of siRNA conjugates and verification of their in vivo activity
[0266] 1. Preparation of siRNA conjugates
[0267] The siRNA conjugates were synthesized by the method of synthesizing the modified siRNA in Reference Example 2, wherein, for the synthesis of the positive strand, the solid support CPG was replaced with a solid support of the GalNAC compound. siRNA ID NO: 168 (i.e., the conjugate of siRNA ID NO: 160 and the ligand L96), siRNA ID NO: 169 (i.e., the conjugate of siRNA ID NO: 163 and the ligand L96), and siRNA ID NO: 170 (i.e., the conjugate of siRNA ID NO: 163 and the ligand DAW40007) were prepared. Wherein, L96 represents
[0268] siRNA ID NO:168:
[0269] SS(5'-3'):gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-L96;
[0270] AS (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u. Agn is adenosine diol nucleic acid
[0271] siRNA ID NO:169:
[0272] SS(5'-3'):gs-gs-uu-Uf-u-Uf-Cf-Uf-ugu–uga–caaa-L96;
[0273] AS(5'-3'): us-Ufs-ugu-Cf-a-Af-Cf-aaga-Af-a-Af-ac-cs-cs-c.
[0274] siRNA ID NO:170:
[0275] SS(5'-3'):gs-gs-uu-Uf-u-Uf-Cf-Uf-uguugacaaa-DAW40007
[0276] AS(5'-3'): us-Ufs-ugu-Cf-a-Af-Cf-aaga-Af-a-Af-ac-cs-cs-c.
[0277] 2. In vivo activity testing of siRNA conjugates
[0278] 1). AAV / HBV transgenic mouse experiment
[0279] Male C57BL / 6 mice were intravenously injected with 1×10 11 vg of rAAV8-1.3HBV (type C) to establish an AAV / HBV mouse model. After 28 days of modeling, the mice were randomly divided into groups for administration (5 mice / group) and injected subcutaneously with a single injection of solvent, control siRNA conjugate siRNA ID NO: 168 (i.e., attached Figure 2 ID168, 3mg / kg (i.e. 3mpk)) and siRNA conjugate siRNA ID NO:169 (i.e. Figure 2 ID169, 1 and 3 mg / kg (i.e., 1 mpk and 3 mpk)), mouse plasma samples were collected on days -3, 7, 14, 21, 28, and 35 after administration, and the mouse plasma HBsAg levels were quantitatively detected. The results are shown in the attached Figure 2 As shown, the horizontal axis is the number of days before and after the first administration, and the vertical axis is the HBsAg content in mouse plasma. The experimental results showed that different siRNA conjugates had a significant inhibitory effect on HBV AAV mouse serum HBsAg after a single administration, and siRNA ID NO: 169 had the strongest inhibitory effect, which was better than 3mg / kg siRNA conjugate siRNA ID NO: 168 at 1mg / kg and 3mg / kg doses, and the inhibition rate of different dose groups of siRNA ID NO: 169 was dose-dependent.
[0280] 2). HBV-Tg transgenic mouse experiment
[0281] Experimental methods
[0282] Experimental animals: HBV-Tg transgenic mice, C57B / 6N-Tg(1.28HBV) / Vst, SPF-grade male, 6-8 weeks old, 16-20 g, purchased from Beijing Weitongda Biotechnology Co., Ltd., animal production certificate number: SCXK(Beijing)2019-0002. The animals were raised by Beijing Weitongda Biotechnology Co., Ltd. and were kept in individual cages.
[0283] Animal grouping: According to the quantitative detection results of mouse serum HBsAg (primary) and HBeAg (secondary), the animals were stratified and randomly divided into groups, with 5 animals in each group.
[0284] Preparation and administration of test products: Calculate the required amount of drug powder according to the purity of each test product. Add the corresponding physiological saline according to the administration concentration of 0.6 mg / mL, and oscillate to mix until it becomes a colorless and transparent liquid. The day of the first administration is defined as day 0. All groups of animals were given a single dose on day 0, and the subcutaneous administration volume was 5 mL / kg. If blood sampling is required on the day of animal administration, the administration will be performed after blood sampling.
[0285] Main outcome measures: The subjects were weighed and blood was drawn once on the 3rd, 7th, 14th, 21st, 28th and 35th days, and serum was separated for determination of HBsAg and HBeAg levels.
[0286] Serum HBsAg and HBeAg level determination: After blood collection, serum is separated and diluted with PBS solution before being sent for testing. 10 μL of serum is taken from each sample and diluted to 500 μL (50 times dilution) with PBS solution. Serum HBsAg and HBeAg levels are measured using the Hepatitis B e Antigen Assay Kit (Mike Biotech) and the Hepatitis B Surface Antigen Assay Kit (Mike Biotech), respectively.
[0287] Experimental results of HBV-Tg transgenic mice
[0288] In the HBV-Tg mouse model experiment, the inhibitory effect of the siRNA conjugate of the present invention on HBsAg is shown in the attached Figure 3 .
[0289] The experimental results showed that compared with the vehicle control group (Vehicle), at a dose of 3 mg / Kg, siRNA conjugate 170 (siRNA ID NO: 170, i.e. Figure 3 The inhibitory activity of siRNA conjugate 170 on HBsAg was significantly better than that of control siRNA conjugate 168 (i.e., siRNA ID NO: 168, i.e., attached Figure 3 168 in ).
[0290] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0291] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A siRNA, characterized in that Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA includes a sense strand and an antisense strand, wherein the antisense strand has a complementary region of at least partial base pairing with the sense strand; wherein the sense strand comprises one of the nucleotide sequences shown in SEQ ID NO:1 to SEQ ID NO:150, or has a difference of no more than 5 nucleotides therefrom; The antisense strand includes one of the nucleotide sequences shown in SEQ ID NO: 151 to SEQ ID NO: 300, or has a difference of no more than 5 nucleotides therefrom.
2. The siRNA according to claim 1, characterized in that The sense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:58, SEQ ID NO:69, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO: 130, SEQ ID NO: 140, SEQ ID NO: 148 and SEQ ID NO: 150; and / or The antisense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO:157, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:196, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:208, SEQ ID NO:219, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:268, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:290, SEQ ID NO:298 and SEQ ID NO:300; Optionally, the sense strand comprises one of the following nucleotide sequences, or differs therefrom by no more than 5 nucleotides: SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:40, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:129 and SEQ ID NO:130; and / or The antisense strand comprises one of the following nucleotide sequences, or has a difference of no more than 5 nucleotides therefrom: SEQ ID NO:162, SEQ ID NO:170, SEQ ID NO:190, SEQ ID NO:243, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:271, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:279 and SEQ ID NO:280; Optionally, the siRNA comprises one or more of the following groups: A sense strand having the nucleotide sequence shown in SEQ ID NO: 12 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 162 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 20 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 170 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO:40 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO:190 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 93 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 243 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 97 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 247 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 98 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 248 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence as shown in SEQ ID NO: 99 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence as shown in SEQ ID NO: 249 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 115 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 265 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 116 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 266 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 121 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 271 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 123 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 273 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 124 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 274 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 125 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 275 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; A sense strand having the nucleotide sequence shown in SEQ ID NO: 129 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and an antisense strand having the nucleotide sequence shown in SEQ ID NO: 279 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides; The sense strand has the nucleotide sequence shown in SEQ ID NO: 130 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides, and the antisense strand has the nucleotide sequence shown in SEQ ID NO: 280 or a nucleotide sequence that differs therefrom by no more than 5 nucleotides.
3. The siRNA according to claim 1 or 2, characterized in that The sense strand and / or antisense strand comprises a 3' overhang and / or a 5' overhang, wherein the 3' overhang or the 5' overhang comprises at least 1 nucleotide, preferably at least 2 nucleotides; Optionally, the sense strand and / or antisense strand comprises a 3' overhang, and the 3' overhang comprises 2 nucleotides.
4. The siRNA according to claim 1 or 2, characterized in that The sense strand comprises 5'-GGUUUUUCUUGUUGACAAA-3' (SEQ ID NO: 330), and the length of the sense strand is no more than 21 nucleotides, the antisense strand comprises 5'-UUUGUCAACAAGAAAAACCCC-3' (SEQ ID NO: 190), and the length of the antisense strand is no more than 23 nucleotides, and each nucleotide in the sense strand and the reaction strand is a modified nucleotide.
5. The siRNA according to any one of claims 1 to 4, characterized in that The sense strand and / or the antisense strand comprises at least one modified nucleotide, and the modified nucleotide is independently and optionally selected from at least one of the following: Non-natural base nucleotides, deoxynucleotides, 2'-fluoro modified nucleotides, 2'-amino modified nucleotides, 2'-O-allyl modified nucleotides, 2'-alkyl modified nucleotides, 2'-O-alkyl modified nucleotides, 2'-methoxyethyl modified nucleotides, locked nucleotides, configuration-restricted nucleotides, 2'-allyl modified nucleotides, abasic nucleotides, morpholino nucleotides, tetrahydropyran modified nucleotides, 1,5-anhydrohexitol modified nucleotides, cyclohexenyl modified nucleotides, PEG modified nucleotides, 5'-phosphoramidate modified nucleotides, 5'-phosphorothioate modified nucleotides, 5'-methylphosphonate modified nucleotides, 5'-phosphate mimetic modified nucleotides, 5'-methylated cytosine modified nucleotides; Optionally, all nucleotides in the sense strand and / or the antisense strand are modified nucleotides, and the modified nucleotides are independently and optionally selected from at least one of 2'-methoxy-modified nucleotides, 2'-fluoro-modified nucleotides and 5'-phosphorothioate-modified nucleotides; Optionally, in the sense strand and / or the antisense strand, 2'-fluoro-modified nucleotides are present at the following positions: The nucleotides at the 5' end of the sense strand are the 5th, 7th, 8th and 9th nucleotides of the starting point; and / or The nucleotides at the 5' end of the antisense strand are the 2nd, 6th, 8th, 9th, 14th and 16th positions of the starting point; Optionally, in the sense strand and / or the antisense strand, 5'-phosphorothioate-modified nucleotides are present at the following positions: The nucleotides at the 5' end of the sense strand are the 1st and 2nd nucleotides of the starting point; and / or The nucleotides at the 5' end of the antisense strand are the 1st and 2nd positions of the starting point, and / or the amino acids at the 3' end of the antisense strand are the 2nd and 3rd positions of the starting point; Optionally, in the sense strand and / or the antisense strand, 2'-methoxy modified nucleotides are present at the following positions: The nucleotides at the 5' end of the sense strand are the 1st, 2nd, 3rd, 4th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th and 19th nucleotides of the starting point; and / or The nucleotide at the 5' end of the antisense strand is the 1st, 3rd, 4th, 5th, 7th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th, 20th or 21st nucleotide of the starting point; Optionally, in the sense strand and / or the antisense strand, 2'-methoxy-modified nucleotides, 2'-fluoro-modified nucleotides and 5'-phosphorothioate-modified nucleotides are present at the following positions: The nucleotides at the 5' end of the sense strand are the 1st, 2nd, 3rd, 4th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th and 19th nucleotides of the starting point; and / or The nucleotide at the 5' end of the antisense strand is the 1st, 3rd, 4th, 5th, 7th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th, 20th or 21st nucleotide of the starting point; and / or The nucleotides at the 5' end of the sense strand are the 5th, 7th, 8th and 9th nucleotides of the starting point; and / or The nucleotides at the 5' end of the sense strand are the 1st and 2nd nucleotides of the starting point; and / or The nucleotides at the 5' end of the antisense strand are the 2nd, 6th, 8th, 9th, 14th and 16th nucleotides of the starting point; and / or The nucleotides at the 5' end of the antisense strand are the first and second positions of the starting point, and / or the nucleotides at the 3' end of the antisense strand are the second and third positions of the starting point.
6. The siRNA according to any one of claims 1 to 5, characterized in that The siRNA includes one of the following siRNA ID NOs: 152-167: Wherein, in the sense strand and the antisense strand, a, g, c and u are 2'-OMe A, 2'-OMe G, 2'-OMe C and 2'-OMe U, respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U, respectively; s indicates that the nucleotide has a 5'-phosphorothioate modification; Optionally, the siRNA includes one of the following siRNA ID NO: 152, siRNA ID NO: 153, siRNA ID NO: 155, siRNA ID NO: 162, siRNA ID NO: 163, siRNA ID NO: 164, siRNA ID NO: 165 and siRNA ID NO: 166: Among them, in the sense strand and the antisense strand, a, g, c and u are 2'-OMe A, 2'-OMe G, 2'-OMeC and 2'-OMeU respectively; Af, Cf, Gf and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G and 2'-fluoro U respectively; s indicates that the nucleotide has a 5'-phosphorothioate modification.
7. A siRNA conjugate, characterized in that include: The siRNA and ligand according to any one of claims 1 to 6; The siRNA is linked to a ligand.
8. The siRNA conjugate according to claim 7, characterized in that The ligand is linked to the sense strand and / or antisense strand; Optionally, the ligand is linked to the sense strand and / or antisense strand via a phosphorothioate bond or a phosphate bond; Optionally, the ligand is linked to the 5' end or the 3' end of the sense strand; and / or The ligand is connected to the 5' end or the 3' end of the antisense strand; Optionally, the ligand comprises at least one N-acetyl-galactosamine; Optionally, the ligand is a GalNAC compound; Optionally, the GalNAC compound includes at least one of L96 or its isomers, DAW4007-4 or its isomers.
9. The siRNA conjugate according to claim 7 or 8, characterized in that The conjugate has the following structure or one of its isomers: wherein each A is independently and optionally the siRNA according to any one of claims 1 to 6; Preferably, A is a siRNA having a sense strand having the nucleotide sequence shown in SEQ ID NO:312 and an antisense strand having the nucleotide sequence shown in SEQ ID NO:
328.
10. A pharmaceutical composition, characterized in that include: The siRNA according to any one of claims 1 to 6 or the siRNA conjugate according to any one of claims 7 to 9; Optionally, it further comprises: a pharmaceutically acceptable carrier or excipient.
11. Use of the siRNA according to any one of claims 1 to 6, the siRNA conjugate according to any one of claims 7 to 9, or the pharmaceutical composition according to claim 10 in the preparation of a drug for inhibiting the expression or activity of a hepatitis B virus gene.
12. Use of the siRNA according to any one of claims 1 to 6, the siRNA conjugate according to any one of claims 7 to 9, or the pharmaceutical composition according to claim 10 in the preparation of a drug for preventing and / or treating diseases related to hepatitis B virus; Optionally, the hepatitis B virus-induced related diseases include acute hepatitis B, acute fulminant hepatitis B, chronic hepatitis B, end-stage liver disease, liver fibrosis, cirrhosis and liver cancer.
